New Products

Anti-MMAE (Monomethyl auristatin E) Antibodies and MMAE Conjugates: For PK/PD Studies on MMAE-ADC

Antibody-drug conjugates (ADCs) are regarded as a powerful immunotherapy that can accurately eliminate cancers without damaging normal tissues. However, their enormously potent toxins pose a challenge for researchers to develop the corresponding antibodies before the animal immunization and clinical trials.

For the sake of a more competent method to facilitate the pharmacokinetics (PK) and pharmacodynamic (PD) evaluation of newly developed ADCs, Creative Diagnostics has developed anti-MMAE antibodies and paired conjugates that are suitable for ADC ELISA assay development. It can be used in the quantitative determination of ADC level in test sample, thereby greatly saving the time and costs.

MMAE (Monomethyl auristatin E) Antibodies and Conjugates

》Find More Cytotoxic Drug Antibodies (DM1/4, MMAF, SN38 etc.)

Highlight Features

  • High purity and lot consistency
  • Validated in ELISA development
  • Reacts with MMAE and MMAE-antibody drug conjugate.
  • No cross-reaction with other ADC analogs

MMAE-mAb-Conjugate Introduction

MMAE-mAb-Conjugate Skeletal Fig.1 MMAE-mAb-Conjugate Skeletal

MMAE (Monomethyl auristatin E) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself, instead, it is linked to a monoclonal antibody which directs it to the cancer cells. In International Nonproprietary Names for mAb-MMAE-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. MMAE as cytotoxic drugs has been reported, it conjugated with antibodies via cleavable linkers (MC-vc-PAB). It is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in pre-clinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. These drugs show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer.

References:

  1. Dosio F; Brusa P, Cattel L. Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components.[J]. Toxins, July, 2011. 3 (12): 848–883.
  2. Haeuw J F, Caussanel V, Beck A. Immunoconjugates, drug-armed antibodies to fight against cancer.[J]. Medecine Sciences M/s, December, 2009. 25(12):1046-1052.
  3. Lambert J M, Morris C Q. Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review[J]. Advances in Therapy, May, 2017. 34(5):1015-1035.
  4. Scotti C, Iamele L, Vecchia L. Antibody–drug conjugates: targeted weapons against cancer[J]. Antibody Technology Journal, January, 2015. (5):1-13.
Inquiry Basket